Form 4: Day One Biopharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Natalie C. Holles, a director of Day One Biopharmaceuticals, acquired stock options to purchase 32,335 shares of common stock on May 23, 2024.
Summary
- On May 23, 2024, Natalie C. Holles, a director of Day One Biopharmaceuticals, Inc. (DAWN), acquired stock options.
- The stock options grant the right to buy 32,335 shares of Day One Biopharmaceuticals' common stock at an exercise price of $13.87.
- The options vest monthly, starting June 23, 2024, with 1/12th of the total grant vesting each month, contingent upon continued service to the company.
- The options expire on May 22, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's value and prospects.
Stakeholder Impact
- Shareholders can use this information to understand insider activity and align their investment strategies accordingly.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of the stock option transaction. |
| 06/23/2024 | Start date for monthly vesting of the stock options. |
| 05/22/2034 | Expiration date of the stock options. |
| 05/28/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.